Category: Treatment
Preprint: Ivermectin was associated with reduced mortality vs Remdesivir
Our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either Ivermectin (1,072) or Remdesivir (40,536). More...
UK SAGE: Four scenarios for the evolution of the pandemic
UK SAGE have recently published a document outlining four different scenarios for the evolution of the pandemic in Britain. More...
Preprint: 75% of Covid ICU patients report symptoms after one year
Of 246 patients who were alive 1 year following ICU treatment for COVID-19, 74.3% reported physical symptoms, 26.2% reported mental symptoms, and 16.2% reported cognitive symptoms. More...
Research: Probiotic improves symptomatic and viral clearance in Covid19 outpatients
Primary outcome of complete remission on day 30 was achieved by 78 (53.1%) in the probiotic group compared to 41 (28.1%) in placebo. More...
It’s the largest global Covid wave EVER
Driven by the new Omicron variant, the world is now being overwhelmed by the largest global Sars-CoV-2 wave EVER. More...
Omicron overpowers monoclonal antibody treatments in early tests
Preliminary experiments suggest that most of the monoclonal antibody treatments for Covid-19 are powerless against Omicron. More...
UK GP: Omicron kills in the same way as classic covid in the elderly
“Omicron spreads like wildfire. Omicron went from one patient in a ward, to 8 patients and 4 staff infected overnight, to 5 wards full (mostly hospital acquired) 4 days later. More...
UKHSA risk assessment for Omicron variant
UK risk assessment for Omicron variant B.1.1.529, dated 3rd December 2021
Transmissibility between humans: Amber – At least as transmissible as currently circulating variants
Omicron is transmitting rapidly and successfully. More...
UK: All travellers will require a PCR test and quarantine until negative to prevent spread of Omicron
At a press conference today, 10 Downing Street announced new measures to combat the potential spread of the Omicron variant in the UK. More...
Merck’s Covid-19 pill Molnupiravir only 30% effective in final analysis
The pharmaceutical company Merck said on Friday that in a final analysis of a clinical trial, its antiviral pill molnupiravir reduced the risk of hospitalization and death among high-risk Covid patients by 30 percent, down from an earlier estimate of 50 percent. More...